Biogen Idec and Sobi report Eloctate study data

Biogen Idec and partner Sobi have announced positive findings from a new study of their haemophilia therapy Eloctate.

Data from the phase III A-LONG study presented at the annual meeting of the International Society on Thrombosis and Haemostasis in Amsterdam revealed that the new long-lasting recombinant factor VIII candidate can offer numerous benefits to patients.

It was shown to help reduce the number of intravenous injections people with haemophilia A require, while also controlling bleeding during and after surgery and addressing acute bleeding episodes.

Eloctate has been submitted for regulatory approval in the US and Australia, with additional filings planned soon.

Dr Glenn Pierce, senior vice-president of global medical affairs and chief medical officer of Biogen Idec's haemophilia therapeutic area, said: "The A-LONG data presented at ISTH support the potential of Eloctate to enable longer intervals between prophylactic injections compared to the current standard of care."

During the congress in Amsterdam, Biogen Idec and Sobi also announced data from the B-LONG trial that showcased the benefits of another of their haemophilia therapies, Alprolix.